What drives pharmaceutical innovation and knowledge exchange? A study supporting the use of Knowledge Management within the pharmaceutical industry by Thomas W. Parsons (7169558) et al.
 1
What drives pharmaceutical innovation and knowledge exchange? 
A study supporting the use of Knowledge Management within the pharmaceutical 
industry 
 
 
Thomas W Parsons1, Thomas W Jackson1 & Ray Dawson1 
 
1Loughborough University 
Department of Computer Science, Loughborough University, 
Loughborough, LE11 3TU, England 
 
t.w.parsons@lboro.ac.uk, r.j.jackson@lboro.ac.uk, r.j.dawson@lboro.ac.uk 
 
 
 
 
 
 
Submitted to OLKC 2006 Conference at the University of Warwick, Coventry on 20th - 
22nd March 2006. 
 2
Abstract 
 
Innovation is a key driver of the pharmaceutical company, from an initial discovery of a 
compound to the final development of a marketable and novel medicine, the web of processes 
to reach a viable end stage requires innovative behaviour backed by accurate knowledge. This 
paper analyses the use, importance and sources of knowledge within the drug development 
process and suggests that a pharmaceutical Knowledge Management strategy should not only 
address capturing the knowledge within the drug processes, but also the knowledge held 
within the social networks of the organisation. 
 
Introduction 
 
Innovation has long been associated with the pharmaceutical industry, the 
development of new medicines is paramount to the longevity of both the organisation and 
society (Cardinal & Hatfield, 2000), yet the complexity of these processes is largely under 
researched and few studies exist which shed light upon how drug innovation actually occurs. 
The following paper aims to shed light upon these hidden processes and address where 
Knowledge Management can aid and enhance the innovative processes within an R&D 
organisation. 
 
Knowledge is regarded by many as the true driver of innovation and an organisation’s 
competitive ability (Spender & Grant, 1996). The pharmaceutical industry is a knowledge 
intensive arena that demands up to date applicable knowledge and to all intents and purposes, 
Knowledge Management research should be able to provide worthwhile benefits to an 
organisation and enhance the drug development processes (Alavi & Leidner, 2001). However 
due to the complexities associated with modern drug development, little research has been 
conducted on the effectiveness of Knowledge Management strategies within the drug 
development industries. Howells (2002) notes the challenge of the pharmaceutical industry is 
to keep abreast of the sheer volume of information and knowledge within the pharmaceutical 
domain, while competing with rivals on the quality and efficacy of its drug products. From a 
strategic perspective the role of the R&D function within large pharmaceutical companies is 
changing, research by Kneller (2003) indicates the basis of drug development is migrating 
from the in-house R&D model, to one of external acquisition of innovation and drug 
technology through Universities and BioTechnology firms. While this transition is occurring, 
research within the drug industry suggests companies are slow to accept such change and 
embrace Knowledge Management strategies as a means to adapt (Davenport & Peitsch, 
2005).  
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Such issues are effecting all pharmaceutical organisations as they compete within the global 
economy, when coupled with the need to assimilate external knowledge into the burgeoning 
wealth of knowledge and information across the large pharmaceutical organisations, such 
change is merely compounding these problems. The following paper uses a series of case 
studies to examine the responses to the changing pattern of innovation within a large UK 
pharmaceutical company and discusses the Knowledge Management measures the 
organisation has implemented to retain a competitive edge. The authors then speculate on 
possible Knowledge Management led strategies which address the mounting challenge of 
effective pharmaceutical knowledge and information management.  
 
Drug Discovery - a web of processes and knowledge 
 
The company under scrutiny is a world leader in a number of therapeutic areas, and these 
include cancer, gastrointestinal, cardiovascular and respiratory related diseases. Within each 
of these Therapeutic Areas the drug development process begins within the Discovery wing of 
the company. Here the knowledge of the employees and strategists is applied to develop 
compounds that are pharmacologically active against a biological target. Such initial stages of 
drug discovery is labelled as the development of a New Chemical Entity (NCE). The NCE is 
designed to have a pharmacologically active effect on a key marker for the disease, whether 
this is to relieve symptoms of a disease, such as lowering blood pressure or attack the root of 
the disease and provide a cure. Once a number of NCEs that specifically target a receptor, 
protein or enzyme involved within the disease state are identified, these compounds are then 
forwarded to the Clinical wing of the organisation. Essentially Discovery is responsible for 
providing and discovering worthwhile NCEs to the organisation. When a suitable NCE is 
forwarded within the organisation to the Clinical wing, it becomes a Candidate Drugs (CDs), 
where the credentials of the compound are verified with regards to their efficacy and 
performance within biological models. Timescales within this process may be up to five 
years, yet there still remains a substantial amount of work to achieve before a CD can be 
released to market, in most cases this is a further six years of work. Only once a CD has 
passed a rigorous series of internal and external control points, trials and safety measures may 
the drug be released to market as a New Medical Entity. At any point within these processes a 
drug may fail to meet strict criteria, thus cutting this attrition and identifying potential failures 
earlier within the processes is essential (Kneller, 2003). Research by Alanine et al. (2003) 
suggests the success of this process overall may be as low as 1-5%, evidently an organisation 
charged with addressing the high failure rate of compounds must address the fundamental 
core processes associated with drug development. 
 
Knowledge is at the crux of drug development and the knowledge required to innovate 
and drive the drug discovery processes may be considered as the main asset of an organisation 
(Kandampully, 2002). KM to all intents and purposes, would appear to be an ideal vehicle 
with which to reduce the amount of resource involved with the laborious process of 
converting a NCE to a NME (Nahapiet & Ghoshal, 1998). The drug discovery processes may 
be viewed from a linear perspective, yet research by Orsenigo et al. (2001) suggests drug 
development functions as a network of interrelated processes and innovations. The 
Knowledge Management literature is clear to promote Knowledge Management as a suitable 
vehicle with which to address the knowledge activities of the employees, yet few papers 
accurately describe the Knowledge Management strategies an organisation should implement. 
Studies by Jennex & Weiss (2002) and KanKanhalli (2001) recognise the benefits of 
Knowledge Management within a research-based organisation, however little research targets 
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the applicability of Knowledge Management within the pharmaceutical R&D environment. 
Research by Schmid & Smith (2004) suggests luck plays an important role within drug 
discovery, while Sundgren & Styhre (2004) promote the role of intuition as a basis for drug 
discovery. The following study begins to clarify the basis of innovation and spread further 
light upon the use and potential of Knowledge Management within the industry.    
Pharmaceutical Innovation and Knowledge Management   
 
This paper is primarily concerned with pharmaceutical innovation, yet the concept of 
pharmaceutical innovation is ill defined. The process of innovation stems from a variety of 
interconnected areas such as competitive advantage, risk management, technological 
management, collaborative activity, creativity and KM amongst other related fields (Nieto, 
2004). Innovation is commonly referred to as the creation of value through the use of such 
assets, whether they are intangible or tangible assets, so in many senses innovation relates to 
the creation of new tangible product (Nonaka & Takeuchi, 1995).  
 
Although innovation may be described as the formation of a tangible product, Cooper (2003) 
and Montes, Moreno & Morales (2005) argue innovation may also be construed as a strategic 
concept, where the option to improve the organisation and therefore induce a competitive 
advantage, arises through the use of innovative business practices. The definition of 
innovative processes with regard to drug development, supplied by Terziovski & Morgan 
(2004) will define the boundaries and form the basis of the study.  
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Terziovski & Morgan (2004) define innovation as:  
 
“A process of creating and developing new products or services through collaborative 
team processes and mechanisms, which utilise and empower the skills and knowledge of the 
people.” 
 
The definition relies upon the provision of knowledge to facilitate product development 
through the use of processes, which allow creative and innovative behaviour. Essentially the 
application of the correct personnel and their knowledge carries a drug development into 
practice. The use of adaptive business process behaviour allows innovation, which in turn 
allows the company to produce marketable products from their knowledge, thoughts mirrored 
by Yeoh & Roth (1999). Studies of innovative practice by Leavitt (2003) within the 
pharmaceutical industry suggest Knowledge Management may play a positive role within 
drug development, particularly with regard to enhancing the access speeds to information and 
knowledge by the employees across the organisational domain. However Knowledge 
Management embraces more facets than technology, Darroch & McNaughton (2002) note 
Knowledge Management seeks to create or locate local knowledge, manage the organisational 
flow of knowledge and ensure the effective use in order to provide a long term cultural benefit 
to the organisation. In light of these benefits, the studies principle aim is to discuss the use of 
Knowledge Management within the organisation and suggest strategies to allow an increase in 
efficiency within the R&D drug development processes. 
Methodology 
 
The following paper is based upon a study which relates to the use of innovative practice and 
drug development innovation within a leading UK pharmaceutical organisation. The 
objectives of the research were: to assess Knowledge Management as an aid to innovative 
work within the drug development realm, propose new Knowledge Management strategies 
and discuss the impact that Knowledge Management may have within the dynamic 
environment of the pharmaceutical innovation with regards to the barriers and enablers of 
Knowledge Management. In order to study these facets the paper is based upon the results of 
thirty three semi-structured interviews conducted with known innovators within the 
pharmaceutical organisation.  
 
Due to the abstract nature of the problem scope, the paper adopts a case study approach in 
under to further define the boundaries of innovation and apply structure to the problem 
(Rowley, 2002). Qualitative data analysis inline with Cresswell (1994) was employed to 
gather and analyse the data, while the sample population was derived from a large workforce 
of over 10,000 personnel and was chosen to provide a broad representation of innovative 
practice within the organisation.  
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The chosen interviewees consisted of senior managers, physicians and research scientists 
within the company, and as such represented a broad cross section across the hierarchies of 
the organisational culture.  
 
A primary criteria for inclusion within the study was an annual recognition award for 
innovative behaviour, where the nominated candidates had performed work relating to the 
development process outside their remit to result in an outstanding contribution. The study 
also included key innovators who were renowned by the senior management, for providing 
maverick contributions within the development of chemical compounds or processes. The use 
of semi-structured interviews throughout the case study was chosen so as to yield a rich 
account of the use of knowledge within the drug development processes and provide the real 
life context of the actors within the social tapestry of the case research area (Yin, 1989). The 
interviews sought to elaborate and reveal the knowledge sharing behaviour of the staff with 
regards to Knowledge Management tools and to yield rich qualitative data concerning the 
innovative processes of key managerial and ground level personnel across the organisations 
R&D domain. Each case study utilises a series of semi-structured interviews, which are based 
upon work by Scarborough et al. (1999), Sundgren & Styhre (2004), Dorabjee et al. (1998) 
and Coombs et al. (1998). The study has yielded rich and detailed qualitative data, not only 
concerning the role of knowledge within drug development, but also the potential use of KM 
within innovation. The results of the analysis and case study will be discussed in further detail 
within the following section. 
Analysis 
 
The results of the research study are now presented and discussed in line with the interview 
structure, the key findings and critical observations, revealed while discussing the role of 
Knowledge Management within the drug development processes. The study examined the 
following areas: 
 
1. Knowledge Management Strategy and Technology 
2. Combining the Social and Technical Aspects of Knowledge Management 
 
The results are intended to provide an insight into the R&D processes, and provide a 
justification for the use of Knowledge Management within the pharmaceutical environment. 
The results uncovered question the importance and relevance of a Knowledge Management 
strategy that aligns with the organisation’s strategy of drug development; while hinting that 
although the areas of technology and organisational knowledge appear distinct, they naturally 
support each other. As such the results provide a number of interesting areas for the 
development of KM strategies and allied areas of further research, which will be covered in 
later papers. 
 
Knowledge Management Strategy and Technology 
 
The interviews were conducted to obtain an accurate qualitative picture of the organisations 
Knowledge Management strategy. While the studied organisation is a market leading R&D 
company, it is also typical of many large organisations. Disparate information and knowledge 
sources lay across the organisation and employees struggle to access relevant information. 
Such is the demand for diverse sources of information and knowledge across pharmaceutical 
drug development, that this aspect was expected, in line with research by Henderson (1994). 
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However the organisation has a long-standing Knowledge Management strategy that has 
attempted to address these discrepancies. In-house research conducted by the IS department, 
utilising web based data capture systems and quantitative surveys has found that the strategy 
would appear to be fulfilling the criteria of knowledge and information sharing, although to 
date little research has attempted to clarify the intangible aspects of this research.  
 
From a theoretical viewpoint, an organisations Knowledge Management strategy should 
provide a route or map by which an organisation may effectively guide its employees in line 
with Knowledge Management methodologies and tools (Jashapara, 2004), yet if such a 
strategy is misaligned little value will be returned (Willoughby, 2003). Examining the 
organisations strategy from an innovators viewpoint reveals the Knowledge Management 
technology falls short. Innovators overwhelmingly rely upon their personal networks of 
colleagues and acquaintances to acquire innovative knowledge. When this factor was 
discussed with regard to the initial sources of innovation, employees suggested that the 
majority of drug innovation is in fact in-licensed or bought into the organisation from external 
research entities. The innovative ideas and research stems directly from the employees 
network of collaborators and acquaintances. Initial ideas appear to be generated externally to 
the company and then acquired by the R&D functions of the organisation, on the 
recommendation of the employees and strategists. Innovators were confident that the 
traditional model of in-house drug innovation suggested by Dimasi et al. (2002) was 
redundant. Senior interviewees suggested upwards of 99% of initial drug work was bought in 
and only then would the organisations resource and knowledge be bought to bear upon the 
development processes. Opinions over the extent of innovation acquisition varied, principal 
scientists and employees connected with the Discovery wing of the organisation alleged the 
majority of Candidate Drugs had their origins external to the organisation. While staff 
involved with progressing Candidate Drugs to market launch within the Clinical wing, 
acknowledged that they worked upon drugs that had originated from the organisation.  
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The discrepancy may be explained by the time scales involved within the drug development 
process, the five year development stages from initial compound to Candidate Drug implies 
that many staff are simply unaware of the origins of the initial drug. While this aspect is not 
overly concerning, the finding has further implications when the knowledge aspect of the 
innovation is discussed. Knowledge within the organisation is a fluid entity and staff of both 
functions were unsure as to how and where to acquire background knowledge residing within 
the organisation on the multitude of Candidate Drugs within the organisation. Staff noted their 
principal means of locating knowledge on the organisations Candidate Drugs, was through 
networks of colleagues, both internal and external. Although this process is fuelling 
innovative processes, the case study found the Knowledge Management strategy of the 
organisation does not reflect this. An employee remarked upon the typical means of 
knowledge acquisition within their work:  
 
“I don’t have time to cover the material so I rely on overviews and headlines, but mainly on 
talking to people as five minutes with someone who’s written five papers is usually enough. 
Within the biomedical literature there is a huge amount of slicing and dicing – so to get to the 
bottom line talking to someone is often much quicker.” 
 
Early Knowledge Management literature such as Wiig (1997) focused upon the capture of 
such knowledge as employee and staff turnover naturally affected the availability of 
knowledge within the organisation. While work such as this advocates capturing such 
knowledge it is still relatively unclear how an organisation may achieve this.  
 
The Knowledge Management strategy employed by the organisation relies upon the 
conglomeration of the existing knowledge and information sources within two principal 
document management systems. Although the systems used to manage documents are 
adequate in that respect, the strategy behind what and how it is stored is lacking. As 
previously noted the interviewees favour the use of knowledge networks to gain knowledge 
and few interviewees actively sought information within the document management stores. It 
is also interesting to note that the location and extent of the knowledge and information 
residing within the employee knowledge networks is not captured, this information is only 
present within the mind of the employee. This finding was investigated further across the 
organisational hierarchy, including scientists, senior directors and physicians within the drug 
processes and was found to be the norm and not an isolated case. Neglecting to address the 
location of knowledge outside of the explicit knowledge stores is considered a key failing of 
Knowledge Management systems in general (Cooper, 2003; Tiwana, 2000). Yet unless the 
organisation adopts a rigid strategy that dictates the employees capture the sources of 
knowledge used within their work, the knowledge and nature of these networks will remain 
unknown.  
 
This finding directly relates the concepts of Human Capital to the availability of knowledge 
within the organisation. Lerner & Merges (1997) note collaboration forms the basis of 
biotechnology interactions and this case study implies they also form the basis of 
pharmaceutical innovation. Edvinsson & Malone (1997) consider Human Capital to be the 
knowledge that an employee will take with them once they leave an organisation. Within this 
study this would appear to be the knowledge or ‘know-how’ of the social networks that are 
intrinsically linked to the drug innovative practices, an observation also found within the 
software development industry (Ashworth & Carley, 2006). Although the Knowledge 
Management strategy of the organisation recognises the need to capture such knowledge, 
there is no physical Knowledge Management provision to achieve this. The strategy focuses 
 9
upon supply the minimum of knowledge needed for the employee to fulfil their role, but 
innovative knowledge appears to be derived from extended personal communities of practice. 
Clearly knowledge within the organisation operates on two tiers, as Adair (2004) suggests 
there is the knowledge to perform ones role and then supplementary knowledge to innovate. 
The organisational Knowledge Management strategy should seek to address the second tier of 
supplementary knowledge, by providing the means and technology to retain such social 
knowledge. The following quote from a senior managerial interviewee, who is responsible for 
leading R&D within multiple disease areas, illustrates the problem associated with the 
discovery, capture and dissemination of innovative knowledge: 
 
“I found that each disease area had done an awful lot of innovative methodology work but 
had refused to implement any learning’s from that, sometimes they even refused to draw 
conclusions.” 
 
This example applies to capturing and enhancing the knowledge and processes of designing 
and running innovative clinical trials. Innovative work had occurred outside of the traditional 
scope of a project, yet employees simply were unaware of how to progress such work further 
and how to apply such work within the organisation once completed. The employees, who 
were within the immediate social network and hence directly involved were aware of the 
potential scope and existence of these projects, yet few outside knew of the work. Ensuring 
that innovative work such as this is not neglected and employees are able to locate and refer 
back to such work, equates to the design of a strategy that not only provides access to the core 
level of process-based knowledge, but also provides sufficient remit to capture this additional 
innovative social knowledge. While the provision of Knowledge Management tools such as 
document management systems, case based reasoning tools and expert systems to capture 
explicit process-based knowledge is established within the organisation; the social aspects of 
knowledge management are neglected within the organisation and within the pharmaceutical 
industry as a whole (Davenport & Peitsch, 2005).  
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Kankanhalli et al. (2003) suggests the use of social IT systems to forward Knowledge 
Management initiatives can support the personalisation of knowledge sources that is required 
in these situations. To examine these finding in greater detail within the context of the 
organisation the following section will examine Knowledge Management tools and strategies 
to support the social networks found internally and externally to the organisation. 
     
Combining the Social and Technical Aspects of Knowledge Management  
 
So far the case study has linked the concepts of human capital with the concept of a second 
tier of innovative knowledge, Human Capital is represented by Edvinsson & Malone (1997) 
as the know how, the experience, flexibility, and creativity of the employee within an 
organisation. As we have witnessed this is the knowledge that drives pharmaceutical 
innovation, yet the organisation is failing to uphold these areas through a Knowledge 
Management strategy.  
 
The case study research and literature by Saito et al. (2006), Gunnlaugsdottir (2003) and Wiig 
(1997) suggests these failings may be addressed through the provision of Knowledge 
Management tools. The mentioned authors suggest collaboration may be supported through 
file sharing, expert location systems, meetings, groupware & decision support technology and 
shared applications. While a sense of community may be supported through discussion 
forums, community management, Web Logs (Blogs), Wikis and social network analysis 
software. With such a variety of tools available to the practitioner it is little wonder that 
within the organisation, the survey revealed an unstructured and under used array of such 
technology, masquerading under the banner of a Knowledge Management strategy. 
Supporting collaboration and knowledge networks requires the active management of these 
communities and social networks. At its simplest sense simply providing a discussion forum 
may aid the formation and dissemination of information within the organisation (Wenger & 
Snyder, 2000). The case study suggests communities of practice that are centred upon 
document management systems exist across the organisation. It appears that where there is a 
purpose, a community of practice forms, Hildreth et al. (2000) defines a community of 
practice as clusters or aggregations of both external and internal sources of knowledge. In this 
light the community or network should be identified and allowed to evolve through the use of 
Knowledge Management technology. This should include document management systems, 
communicative media and traditional face-to-face interaction, to become a working 
community capable of providing the human capital necessary to drive innovation.  
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Thus a Knowledge Management strategy should address this aspect, sparking initial 
community formation around drug projects, followed by the provision of specific tools to 
encourage collaboration across the organisation and capture the minutiae of the knowledge 
networks. It is well known that technology-aided collaboration is widely adopted by R&D 
organisations that are seeking to leverage intellectual capital and knowledge assets from their 
workforce in order to enhance product development processes (Lemon, 2004). What is 
unclear however, is whether the focus should rest with tools such as discussion forums, Web 
Logs (Blogs), Wikis or with simple groupware document based systems. What is interesting 
within the organisation is the interviewees unanimously accepted and visualised using such 
additional collaborative systems such as Web Logs and Wikis, when provided with visual 
examples of these tools, an employee commented:  
 
“Personnel want to share best practices and learn from others within the company, we have 
to have a culture that makes it easy to share knowledge and learning“   
 
Supplying the means to achieve this via technology may allow innovation through the 
formation of knowledge networks, in essence a combination of social and collaborative 
software specifically tailored to target the second tier of innovative knowledge.  
 
A further important aspect of the research suggests that the provision of social software is 
particularly important on the interface of organisational departments. In this case between the 
Discovery wing and the Clinical wing. Drug projects within the organisation progress in a 
linear manner as in a traditional drug discovery model (DiMasi et al. 2003). Yet the 
knowledge interactions surrounding these processes and documentation is an iterative, double 
loop learning process. The discovery of double looped learning implies the organisation 
actively challenges drug development assumptions and processes, rather that simply reacting 
to a challenge, as is the case regarding single loop learning (Rubenstein-Montano et al., 
2001). Although the study recognises that such work occurs, little capture or dissemination of 
this knowledge and innovative is then carried out using the Knowledge Management tools. 
An overview of the drug development process and the tiers of knowledge that are inherent 
within the organisations drug processes is illustrated in Figure 1. The diagram in Figure 1 
illustrates that the traditional linear processes of drug development and project documentation 
occurs as a series of milestones. Within these processes the study revealed that knowledge 
loops and collaborative practice occur across multiple processes and multiple actors, which 
are in fact fuelling innovation within the organisation.  
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The model derived from the case study work does not however address the sources of 
innovation. As previously discussed, the initial innovative compound is increasingly likely to 
be sourced externally to the organisation. This process essentially is an acquisition of 
intellectual capital, yet the study revealed that rarely is the human capital i.e. the expertise and 
know-how behind the innovation captured and disseminated throughout the organisation. 
Employees within the Discovery organisation simply acquire the rights to a compound and 
then revalidate existing data and information regarding the drug performance metrics in-
house. In a similar stance Clinical employees also expressed a mistrust of initial external data 
and required revalidation of public clinical data in-house, including peer reviewed journal 
findings. While the study found collaborations with external sources of innovative knowledge 
do occur, they are unstructured and rely upon traditional communications media, such as 
email, face to face and the telephone. Attempts by other employees to discover knowledge on 
external drug acquisitions and collaborations thus fails, resulting in a reiteration of this 
process with different actors across the organisation.  
 
In light of the case study findings, conclusions and recommendations relating to innovation 
and social networks will now be discussed. Further research and possible avenues for a 
Knowledge Management strategy to drive innovation are then suggested.  
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Figure 1. An overview of the Drug Development Processes  
        
Conclusions and Recommendations 
 
The study has revealed a changing model of pharmaceutical innovation, one where in-house 
R&D has given way to the process of intellectual capital acquisition. However this process is 
far from adequate, while the rights to a compound are acquired the associated human capital 
is often overlooked. The innovative knowledge within internal and external collaborations 
constitutes an integral aspect of the human capital within the organisation. Capturing and 
encouraging this knowledge of collaboration through social Knowledge Management tools 
such as discussion forums, Web Blogs and Wikis would thus appear to be a prudent strategy. 
However there is an attitude of mistrust between the R&D functions of the organisation and 
external organisations R&D companies. This requires careful consideration and suggests 
further research with the application of specific collaborative tools is necessitated. The 
research suggests that tailoring collaborative tools to specific projects is a recommended 
strategy. Aligning the resource needs of the employees with a Knowledge Management 
strategy that not only provides base project knowledge but also allows the means to facilitate 
and mange internal and external interaction so as to drive innovation. As the pharmaceutical 
industry is an inherently high-risk area, failure at any point of the development process results 
in a substantial resource cost. Employing a tailored and collaborative Knowledge 
Management strategy in line with the organisational strategy could certainly help to address 
these issues and aid drug development.   
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